Lataa...
Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that is associated with severe functional impairment and a poor prognosis. Ambrisentan is a selective endothelin type A receptor antagonist approved for the treatment of patients with PAH World Health Organiz...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3652514/ https://ncbi.nlm.nih.gov/pubmed/23674888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S30949 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|